Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 3/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9709904 | 0.89 | AGTR1 (0.46) | AGTR1AGTR2CYP2C19ACP1MEN1 | |
| SCHEMBL9709757 | 0.88 | AGTR1 (0.52) | AGTR1AGTR2ACP1PDE4APDE4B | |
| SCHEMBL9709854 | 0.88 | MEN1 (0.63) | AGTR1AGTR2ACP1MEN1KMT2A | |
| SCHEMBL9709759 | 0.88 | AGTR1 (0.45) | AGTR1AGTR2ACP1MEN1KMT2A | |
| SCHEMBL9709642 | 0.87 | AGTR1 (0.48) | AGTR1AGTR2MEN1KMT2A | |
| SCHEMBL9709600 | 0.87 | AGTR1 (0.48) | AGTR1AGTR2MEN1KMT2A | |
| SCHEMBL3055352 | 0.87 | ACP1 (0.45) | AGTR1AGTR2CYP2C19ACP1MEN1 | |
| SCHEMBL9709866 | 0.86 | AGTR1 (0.47) | AGTR1AGTR2PDE4APDE4BPDE4C | |
| SCHEMBL9709673 | 0.86 | PDE4A (0.47) | AGTR1AGTR2ACP1PDE4APDE4B | |
| SCHEMBL9710208 | 0.86 | AGTR1 (0.47) | AGTR1AGTR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | claimed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | claimed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | claimed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | claimed |
| WO-1992022533-A1 | 4-AMINOQUINOLINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE UPJOHN COMPANY (US) | 1992-12-23 | — | — | WO | claimed |
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-1992022533-A1 | 4-AMINOQUINOLINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE UPJOHN COMPANY (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GDI2, GDI1, NQO2 | AGTR1 1294/4885AGTR2 1327/4885CYP2C19 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.